Howard Goldring, founder of Delmore Asset Management, says that Abbvie's increased offer for Shire is "very good" and discusses what a deal would mean for both companies.
CNBC's Meg Tirrell reports there are currently 67 medicines in development for Alzheimer's, with the biggest players in the space including Eli Lilly, Roche/Genentech and Biogen.
CNBC's Meg Tirrell reports on how the pharmaceutical industry is dealing with the Alzheimer's epidemic.
Ron Cohen, Acorda Therapeutics CEO, discusses merger activity in the pharma sector and whether his company is planning an acquisition.
The muscular dystrophy drug seems to slow the decline in walking ability, reports CNBC's Meg Tirrell.
CNBC's Meg Tirrell reports Allergan CEO David Pyott told "Mad Money" host Jim Cramer Valeant's he is keeping his options open on acquisitions.
Narcotics prosecutors say a NYC hospital's former pharmacy chief stole nearly 200,000 oxycodone pills over more than five years.
The big driver in this is chronic diseases, says Sanofi CEO Chris Viehbacher, explaining how big pharma is preparing for the onslaught of aging baby boomers heading towards retirement age.
CNBC's Meg Tirrell, takes a look at how America¿s baby boomer generation will likely affect the pharmaceutical industry.
CNBC's Scott Cohn follows up on his investigation into the high cost of prescription drugs and reports how consumers can protect themselves from getting fake medicine.
While there are weaknesses in the alternative market of prescription drugs, the risks are not always as serious as some claim.
Internet drugstores and their facilitators may claim to be safe, low-cost alternatives to pharmacies. But consumers need to be cautious.
Due to the high cost of prescription drugs, many in the U.S. look overseas to save money. CNBC's Scott Cohn discusses if people are putting themselves at risk or beating big drug companies at their own game.
CNBC's Scott Cohn reports many Americans are trying to save money on prescription drugs by buying them online, but big pharma is fighting back.
Pfizer paid a "nominal fee" to cover expenses related to the facility inspection, and to obtain a certification, a Pfizer spokeswoman said.
The idea is to keep the generic DNA but not the generic margins, says Brent Saunders, Actavis CEO, discussing his company's acquisition of Forest Labs and its long-term growth plans. Saunders also weighs in on corporate tax reform.
The FDA approved MannKind's inhaled insulin drug Afrezza. CNBC's Meg Tirrell has the details of the approval.
Kokou Agbo-Bloua, head of equity and derivative strategy for Europe at BNP Paribas, says that Pfizer is likely to submit another bid to acquire AstraZeneca as a deal would still make "a lot of sense".
CNBC's Meg Tirrell speaks to Vertex Pharmaceuticals CEO Dr. Jeffrey Leiden, about its promising two-drug cystic fibrosis treatment, and what it means for sufferers of the disease. Leiden also explains what goes into the pricing of an "orphan drug."
CNBC's Meg Tirrell explains how cystic fibrosis occurs in the body, and the breakthrough announcement from Vertex Pharmaceuticals.